{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Metastatic+Castration-Resistant+Prostate+Cancer&page=2",
    "query": {
      "condition": "Advanced Metastatic Castration-Resistant Prostate Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Metastatic+Castration-Resistant+Prostate+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T22:25:06.075Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04925284",
      "title": "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Cervical Cancer",
        "SCCHN",
        "Pancreatic Cancer",
        "Esophageal SCC",
        "Metastatic Castration-resistant Prostate Cancer",
        "Triple Negative Breast Cancer",
        "Hormone Receptor-positive Breast Cancer",
        "Epithelial Ovarian Cancer",
        "Endometrial Cancer",
        "Tissue Factor-Expressing Solid Tumors"
      ],
      "interventions": [
        {
          "name": "XB002",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 269,
      "start_date": "2021-06-07",
      "completion_date": "2025-03-10",
      "has_results": false,
      "last_update_posted_date": "2025-04-04",
      "last_synced_at": "2026-07-23T22:25:06.075Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04925284"
    },
    {
      "nct_id": "NCT04104776",
      "title": "A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, T-Cell",
        "Mesothelioma, Malignant",
        "Prostatic Neoplasms, Castration-Resistant",
        "Endometrial Cancer",
        "Ovarian Clear Cell Carcinoma",
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Tulmimetostat",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2019-09-18",
      "completion_date": "2030-02-27",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-07-23T22:25:06.075Z",
      "location_count": 22,
      "location_summary": "Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 14 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04104776"
    },
    {
      "nct_id": "NCT04541225",
      "title": "Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma",
        "Glioma, Malignant",
        "Glioma, Mixed",
        "Glial Cell Tumors",
        "Breast Cancer",
        "Breast Carcinoma",
        "Cancer of Breast",
        "Cancer of the Breast",
        "Breast Tumor",
        "Malignant Tumor of Breast",
        "Advanced Breast Cancer",
        "Advanced Breast Carcinoma",
        "Metastatic Breast Cancer",
        "Metastatic Breast Carcinoma",
        "Prostate Cancer",
        "Prostatic Cancer",
        "Cancer of Prostate",
        "Cancer of the Prostate",
        "Prostate Neoplasm",
        "Castrate Resistant Prostate Cancer",
        "Castration-resistant Prostate Cancer",
        "Castration Resistant Prostatic Neoplasms",
        "Glioblastoma",
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "NUV-422",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nuvation Bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2020-12-08",
      "completion_date": "2022-08-31",
      "has_results": false,
      "last_update_posted_date": "2023-07-14",
      "last_synced_at": "2026-07-23T22:25:06.075Z",
      "location_count": 12,
      "location_summary": "Tucson, Arizona • Miami, Florida • Boston, Massachusetts + 9 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04541225"
    },
    {
      "nct_id": "NCT01262664",
      "title": "A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Prohibitin-TP01",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2012-05-24",
      "completion_date": "2019-01-02",
      "has_results": false,
      "last_update_posted_date": "2019-01-04",
      "last_synced_at": "2026-07-23T22:25:06.075Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01262664"
    },
    {
      "nct_id": "NCT02793219",
      "title": "Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Sipuleucel-T",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2016-12",
      "completion_date": "2021-07",
      "has_results": false,
      "last_update_posted_date": "2017-10-30",
      "last_synced_at": "2026-07-23T22:25:06.075Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02793219"
    },
    {
      "nct_id": "NCT03829436",
      "title": "TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Metastatic Castration Resistant Prostate Cancer",
        "Renal Cell Carcinoma",
        "Non-small Cell Lung Cancer",
        "Colorectal Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Triple-Negative Breast Cancer",
        "Urothelial Carcinoma",
        "Cholangiocarcinoma",
        "GastroEsophageal Cancer",
        "Pancreatic Cancer",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Part 1 TPST-1120",
          "type": "DRUG"
        },
        {
          "name": "Part 2 TPST-1120 + nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Part 3 TPST-1120",
          "type": "DRUG"
        },
        {
          "name": "Part 4 TPST-1120 + nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tempest Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2019-03-20",
      "completion_date": "2022-09-07",
      "has_results": false,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-07-23T22:25:06.075Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Miami, Florida • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03829436"
    },
    {
      "nct_id": "NCT03016741",
      "title": "Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Castration-Resistant Prostatic Cancer",
        "Metastatic Prostate Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Stage IV Prostate Cancer",
        "Hormone-Refractory Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "GnRH agonist/antagonist",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 100,
      "start_date": "2017-03-31",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-07-23T22:25:06.075Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03016741"
    },
    {
      "nct_id": "NCT07667400",
      "title": "Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Paranasal Sinus Neoplasms",
        "Nasopharyngeal Carcinoma",
        "Oropharyngeal Squamous Cell Carcinoma",
        "Hypopharyngeal Cancer",
        "Carcinoma of Larynx",
        "Oral Squamous Cell Carcinoma",
        "Salivary Gland Cancer",
        "Adenoid Cystic Carcinoma",
        "Prostate Cancer",
        "Metastatic Castration Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "SX-682",
          "type": "DRUG"
        },
        {
          "name": "DTX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 120,
      "start_date": "2026-07-28",
      "completion_date": "2037-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-07-23T22:25:06.075Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07667400"
    },
    {
      "nct_id": "NCT00511576",
      "title": "Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Lung Cancer",
        "Pulmonary Cancer",
        "Non-Small-Cell Lung Carcinoma",
        "Prostate Cancer",
        "Prostatic Cancer",
        "Gastric Cancer",
        "Stomach Cancer"
      ],
      "interventions": [
        {
          "name": "MGCD0103 & Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2007-08",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2015-01-08",
      "last_synced_at": "2026-07-23T22:25:06.075Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00511576"
    },
    {
      "nct_id": "NCT03217747",
      "title": "Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Castration-Resistant Prostate Carcinoma",
        "Malignant Solid Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Prostate Carcinoma",
        "Prostate Carcinoma Metastatic in the Bone",
        "Refractory Malignant Solid Neoplasm",
        "Stage IV Prostate Cancer AJCC v8",
        "Stage IVA Prostate Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Ivuxolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Utomilumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 173,
      "start_date": "2017-08-02",
      "completion_date": "2026-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-07-23T22:25:06.075Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03217747"
    }
  ]
}